This is a desirable action because, understanding MASLD in the context of overall metabolic disorders, attention should be paid to antioxidant interventions in the state of overweight and/or obesity, and in cardiological problems accompanied by increased concentration of interleukin-6 (IL-6), IL-1β, or tumor necrosis factor α (TNF-α), or an increased percentage of CD8 lymphocytes. The gene discussed is TNF; the disease is metabolic disease.